Ceesay Abraham

CIK 00017221405 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001722140

Recent Transactions

50 trades

Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-06-29$40.34/sh−876→ 548,027 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-06-29$39.77/sh−7,344→ 548,903 total
Award
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.$CRL
Common Stock
2026-05-08$177.62/sh+1,438→ 2,384 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-02-18$29.80/sh−2,100→ 20,729 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-02-18$29.05/sh−3,552→ 558,528 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-02-18$29.80/sh−2,281→ 556,247 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-02-18$29.04/sh−2,983→ 22,829 total
Award
Rapport Therapeutics, Inc.$RAPP
Stock Option (Right to Buy)
2026-02-02+428,000→ 428,000 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-01-20$26.11/sh−5,083→ 25,812 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2026-01-20$26.12/sh−5,833→ 562,080 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-12-17$28.84/sh−2,147→ 33,831 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-12-17$30.04/sh−2,421→ 31,410 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-12-17$31.04/sh−600→ 567,913 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-12-17$31.04/sh−515→ 30,895 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-12-17$30.04/sh−2,792→ 568,513 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-12-17$28.84/sh−2,441→ 571,305 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-11-17$25.44/sh−2,841→ 35,978 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-11-17$24.91/sh−2,242→ 38,819 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-11-17$24.92/sh−2,777→ 576,802 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-11-17$25.43/sh−3,056→ 573,746 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-10-15$26.14/sh−1,186→ 579,579 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-10-15$25.75/sh−4,328→ 41,816 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-10-15$26.17/sh−755→ 41,061 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-10-15$25.72/sh−4,647→ 580,765 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-09-17$26.30/sh−34,885→ 46,844 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-09-17$26.87/sh−1,400→ 585,412 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-09-17$27.04/sh−700→ 46,144 total
Sale
Rapport Therapeutics, Inc.$RAPP
Common Stock
2025-09-17$26.30/sh−39,435→ 586,812 total
Sale
Pacira BioSciences, Inc.$PCRX
Common Stock
2025-09-04$27.19/sh−2,354→ 9,039 total
Award
Pacira BioSciences, Inc.$PCRX
Common Stock
2025-06-11+6,163→ 11,393 total
Award
Pacira BioSciences, Inc.$PCRX
Stock Option (Right to Buy)
2025-06-11+11,279→ 11,279 total
Award
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.$CRL
Stock Options (Right to Buy)
2025-06-02$135.04/sh+2,082→ 2,082 total
Award
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.$CRL
Common Stock
2025-06-02$135.04/sh+946→ 946 total
Award
Rapport Therapeutics, Inc.$RAPP
Stock Option (Right to Buy)
2025-02-03+428,000→ 428,000 total
Award
Pacira BioSciences, Inc.$PCRX
Common Stock
2024-06-12+5,230→ 5,230 total
Award
Pacira BioSciences, Inc.$PCRX
Stock Option (Right to Buy)
2024-06-12+12,179→ 12,179 total
Award
Rapport Therapeutics, Inc.$RAPP
Stock Option (Right to Buy)
2024-06-06+530,647→ 530,647 total
Award
Pacira BioSciences, Inc.$PCRX
Stock Option (Right to Buy)
2023-10-06+30,967→ 30,967 total
Award
Cerevel Therapeutics Holdings, Inc.
Restricted Stock Units
2023-02-06+29,083→ 29,083 total
Award
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2023-02-06+114,445→ 114,445 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-09-08$32.50/sh−19,210→ 0 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-09-08−19,210→ 365,009 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-09-08$13.17/sh+19,210→ 19,210 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-08-22$13.17/sh+9,605→ 9,605 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-08-22$32.50/sh−9,605→ 0 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-08-22−9,605→ 384,219 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-08-15$13.17/sh+9,606→ 9,606 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-08-15$34.12/sh−9,606→ 0 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-08-15−9,606→ 393,824 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2022-08-08$37.75/sh−9,606→ 9,605 total

Companies

Recent Filings

Address

RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100

BOSTON, MA, 02110

View on SEC.gov